Construction and Validation of a Practical Prognostic Index for Patients with Metastatic Breast Cancer

Patients’ understanding of their own disease and survival potential in patients with metastatic breast cancer. Breast Cancer Res Treat. 61: 145-150, 2000.

A Phase II Study of High-dose Epirubicin (EPI) plus Cyclophosphamide (CPA) with G-CSF for Breast Cancer Patients with Visceral Metastases or Hormone-independent Tumors: A Trial of the Japan Clinical Oncology Group.

A phase I/II Study of Continuous Intra-arterial Chemotherapy Using an Implantable Reservoir for the Treatment of Liver Metastases from Breast Cancer: A Japan Clinical Oncology Group (JCOG) Study 9113

Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer

Tamoxifen versus tamoxifen plus doxorubicin and cyclophosphamide as adjuvant therapy for node-positive postmenopausal breast cancer: results of a Japan Clinical Oncology Group Study (JCOG9401)

Tamoxifen plus tegafur-uracil (TUFT) versus tamoxifen plus Adriamycin (doxorubicin) and cyclophosphamide (ACT) as adjuvant therapy to treat node-positive premenopausal breast cancer (PreMBC): results of Japan Clinical Oncology Group Study 9404.

Phase III trial of doxorubicin plus cyclophosphamide (AC), docetaxel, and alternating AC and docetaxel as front-line chemotherapy for metastatic breast cancer: Japan ClinicalOncology Group trial (JCOG9802).

Final results of a safety and efficacy trial of preoperative sequential chemo-radiation therapy for the nonsurgical treatment in early breast cancer: Japan Clinical Oncology Group Study JCOG0306.

A Randomized Controlled Trial Comparing Primary Tumour Resection Plus Systemic Therapy With Systemic Therapy Alone in Metastatic Breast Cancer (PRIM-BC): Japan Clinical Oncology Group Study JCOG1017. 

Resection of the primary tumor in stage IV breast cancer

Significance of primary lesion resection in Stage IV breast cancer.

Intensive vs. Standard Post-Operative Surveillance in High-Risk Breast Cancer Patients (INSPIRE): Japan Clinical Oncology Group Study JCOG1204

Current approach and future perspective for ductal carcinoma in situ of the breast.

A randomized phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: Japan Clinical Oncology Group Study (JCOG1607, HERB TEA study).

Clinicopathological predictors of postoperative upstaging to invasive ductal carcinoma (IDC) in patients preoperatively diagnosed with ductal carcinoma in situ (DCIS): a multi-institutional retrospective cohort study.

Prospective observational study estimating willingness-to-pay for breast cancer treatments through contingent valuation method in Japanese breast cancer patients (JCOG1709A).

Nuclear grade and comedo necrosis of ductal carcinoma in situ as histopathological eligible criteria for the Japan Clinical Oncology Group 1505 trial: an interobserver agreement study.

Current status of PD-1/PD-L1 blockade immunotherapy in breast cancer.

Current Status of Advance Care Planning and End-of-life Communication for Patients with Advanced and Metastatic Breast Cancer.

Omitting surgery for early breast cancer showing clinical complete response to primary systemic therapy.

Adjuvant and neoadjuvant therapy for breast cancer.

Durable complete response in HER2-positive breast cancer: a multicenter retrospective analysis.

TNM classification of malignant tumors (Breast Cancer Study Group).

Distinct gene expression profiles between primary breast cancers and brain metastases from pair-matched samples.

Current status of postmastectomy radiation therapy in T1-2 breast cancer with limited positive lymph nodes in Japan: Japan Clinical Oncology Group Survey.

Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer.

The transition of breast cancer treatment and Japan Clinical Oncology Group research over two decades.